Italia markets closed
  • Reuters

    UPDATE 1-Big banks face probe over NDAs in swaps, clearing businesses, Bloomberg reports

    The Commodity Futures Trading Commission (CFTC) has reached out to a number of banks, including JPMorgan Chase, Bank of America and Citigroup to see if they have been preventing would-be whistleblowers from speaking out, Bloomberg News reported on Wednesday. CFTC is asking banks for non-disclosure agreements in their swaps and clearing businesses, and has also sought employment and customer agreements in those businesses, the report added, citing people familiar with the matter.

  • Reuters

    Five Eyes countries working to fight critical minerals dumping, Canada minister says

    Canada and its Five Eyes Alliance partners are working on put forward a response to tackle the price manipulation of critical metals, Canada's Finance Minister Chrystia Freeland said on Tuesday. The U.S., Britain, Canada, Australia and New Zealand have what is called the Five Eyes intelligence sharing network and the finance ministers from these countries met last Thursday for the spring session of the International Monetary Fund (IMF) in Washington. Freeland said that she and her counterparts from the Five Eyes Alliance discussed last week on how these countries could "friendshore" their critical minerals supply chain to fight the dumping of critical minerals in the international market by large producing countries, such as China and Indonesia.

  • GlobeNewswire

    Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

    First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51% Day One receives rare pediatric disease priority review voucher Conference call and webcast to be April 24, 8:30 a.m. Eastern Time BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceuti